TY - JOUR
T1 - Hepatic fibrosis — new therapeutic approaches
AU - Schiff, Eugene R.
PY - 1991/4/4
Y1 - 1991/4/4
N2 - THE management of chronic liver disease, particularly cirrhosis, has focused primarily on treating and preventing the complications of portal hypertension. Unfortunately, there is no therapy that has been proved to prevent progressive hepatic fibrosis or cirrhosis. The use of colchicine, one of the oldest known drugs, has been advocated as a means of preventing and even reversing hepatic fibrosis in patients with alcoholic or nonalcoholic cirrhosis.1 However, many physicians are skeptical, and there have been calls for another randomized, controlled trial, since the drop-out rate and sampling errors inherent in the blind liver-biopsy techniques used in the reported trials could.
AB - THE management of chronic liver disease, particularly cirrhosis, has focused primarily on treating and preventing the complications of portal hypertension. Unfortunately, there is no therapy that has been proved to prevent progressive hepatic fibrosis or cirrhosis. The use of colchicine, one of the oldest known drugs, has been advocated as a means of preventing and even reversing hepatic fibrosis in patients with alcoholic or nonalcoholic cirrhosis.1 However, many physicians are skeptical, and there have been calls for another randomized, controlled trial, since the drop-out rate and sampling errors inherent in the blind liver-biopsy techniques used in the reported trials could.
UR - http://www.scopus.com/inward/record.url?scp=0025828520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025828520&partnerID=8YFLogxK
U2 - 10.1056/NEJM199104043241409
DO - 10.1056/NEJM199104043241409
M3 - Editorial
C2 - 2002822
AN - SCOPUS:0025828520
VL - 324
SP - 987
EP - 989
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 14
ER -